- Home
- STTK vs MUA Comparison
STTK vs MUA Comparison
Compare STTK & MUA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | MUA |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 652.4M | 666.0M |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | STTK | MUA |
|---|---|---|
| Price | $5.65 | $9.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $15.40 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 362.7K |
| Earning Date | 11-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.72 | $9.13 |
| 52 Week High | $8.33 | $11.26 |
Technical Indicators
Market Signals| Indicator | STTK | MUA |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 58.63 |
| Support Level | $5.19 | $9.62 |
| Resistance Level | $6.00 | $9.84 |
| Average True Range (ATR) | 0.36 | 0.15 |
| MACD | 0.04 | 0.06 |
| Stochastic Oscillator | 43.49 | 93.08 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.